MicroRNAs (miRNAs) play a vital role in regulating gene expression and are associated with a variety of cancers， including breast cancer. Their distorted and unique expression is a potential marker in clinical diagnoses and prognoses. Thus， accurate determination of miRNA expression levels is a prerequisite for their applications. However， the assays currently available for miRNA detection typically require pre-enrichment， amplification and labeling steps， and most of the assays are only semi-quantitative. Therefore， we developed a quasi-direct liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based targeted proteomics approach to quantify target miRNA by innovatively converting the miRNA si... More
MicroRNAs (miRNAs) play a vital role in regulating gene expression and are associated with a variety of cancers， including breast cancer. Their distorted and unique expression is a potential marker in clinical diagnoses and prognoses. Thus， accurate determination of miRNA expression levels is a prerequisite for their applications. However， the assays currently available for miRNA detection typically require pre-enrichment， amplification and labeling steps， and most of the assays are only semi-quantitative. Therefore， we developed a quasi-direct liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based targeted proteomics approach to quantify target miRNA by innovatively converting the miRNA signal into the mass response of a reporter peptide via a covalently immobilized DNA-peptide probe. Specifically， the probe containing the targeted proteomics-selected substrate/reporter peptide， GDRAVQLGVDPFR/AVQLGVDPFR， and the DNA sequence complementary to the target miRNA (i.e.， miR-21) was first immobilized on APMTS modified silica nanoparticles using PDITC. After the immobilized probe was recognized and hybridized with the target miRNA， the excess probe was degraded using MBN and followed by a trypsin digestion of the hybrids. The reporter peptide was released and quantified using LC-MS/MS. The obtained LOQ was 5 pM. Finally， the developed assay was used for the quantitative analysis of miR-21 in breast cells and tissue samples.
